Intravitreal Bevacizumab Alone or Combined with Macular Laser Photocoagulation for Recurrent or Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion

Table 2

Mean best corrected visual acuity and central subfield thickness at different points.

	BCVA (logMAR)	𝑃 value	CST (𝜇m)	𝑃 value
Baseline	0.55±0.33		478.1±192.9
1 month	0.40±0.29		296.1±108.9
3 months	0.37±0.27		340.0±98.7
6 months	0.40±0.25	<0.05*	305.0±127.9	<0.01^†

BCVA = best corrected visual acuity; CST = central subfield thickness; logMAR = logarithm of the minimal angle of resolution.
Mean BCVA and mean CST assessed by spectral domain optical coherence tomography at baseline, 1 month, 3 months, and 6 months after the initial retreatment.
^∗𝑃<0.05 and ^†𝑃<0.01, compared with baseline values (just before the second intravitreal bevacizumab treatment).